NCT04425382

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar

Efficacy and Safety of Darunavir/Cobicistat vs. Lopinavir/Ritonavir in the Management of Patients With COVID-19 Pneumonia in Qatar

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 400 (actual)
• Sponsor: Hamad Medical Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Coronavirus Disease 2019 (COVID-19) is a disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus. It was first isolated in Wuhan, China in December 2019 and then rapidly spread to the rest of the world posing a severe threat to global health. Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes. Protease inhibitors are one of the proposed agents, but their use is limited to their significant drug interactions and side effects. The aim of this study is to compare the efficacy and safety outcomes of Darunavir/Cobicistat versus Lopinavir /Ritonavir in the treatment of patients with COVID-19 pneumonia in Qatar.

Conditions

• Coronavirus
• COVID
• Pneumonia

Interventions

Type	Name	Description
DRUG	Darunavir/Cobicistat	Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily
DRUG	Lopinavir/Ritonavir	Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily

Timeline

• Start date: 2020-03-01
• Primary completion: 2020-07-31
• Completion: 2020-09-30
• First posted: 2020-06-11
• Last updated: 2022-08-16

Locations

1 site across 1 country: Qatar

Regulatory

• FDA-regulated drug study